Roivant Sciences Management
Management criteria checks 2/4
Roivant Sciences' CEO is Matt Gline, appointed in Jan 2021, has a tenure of 4.92 years. total yearly compensation is $163.29M, comprised of 0.4% salary and 99.6% bonuses, including company stock and options. directly owns 0.012% of the company’s shares, worth $1.85M. The average tenure of the management team and the board of directors is 4.1 years and 4.3 years respectively.
Key information
Matt Gline
Chief executive officer
US$163.3m
Total compensation
| CEO salary percentage | 0.44% |
| CEO tenure | 4.9yrs |
| CEO ownership | 0.01% |
| Management average tenure | 4.1yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Roivant Sciences: Brepocitinib And Roadmap Still Underpriced
Nov 13Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Apr 23Industry Analysts Just Upgraded Their Roivant Sciences Ltd. (NASDAQ:ROIV) Revenue Forecasts By 21%
Feb 12
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)
Feb 05
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas.Roivant Sciences: A Biotech Growth Play With Major Ambitions
Dec 04Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Oct 22Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
Aug 22Roivant Sciences: Executing On Huge Buyback Program With More To Come
Jun 02Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
Mar 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$701m |
| Jun 30 2025 | n/a | n/a | -US$775m |
| Mar 31 2025 | US$163m | US$725k | -US$545m |
| Dec 31 2024 | n/a | n/a | -US$402m |
| Sep 30 2024 | n/a | n/a | US$5b |
| Jun 30 2024 | n/a | n/a | US$5b |
| Mar 31 2024 | US$738k | US$725k | US$5b |
| Dec 31 2023 | n/a | n/a | US$5b |
| Sep 30 2023 | n/a | n/a | -US$927m |
| Jun 30 2023 | n/a | n/a | -US$1b |
| Mar 31 2023 | US$49m | US$725k | -US$783m |
| Dec 31 2022 | n/a | n/a | -US$1b |
| Sep 30 2022 | n/a | n/a | -US$1b |
| Jun 30 2022 | n/a | n/a | -US$1b |
| Mar 31 2022 | US$725k | US$725k | -US$845m |
| Dec 31 2021 | n/a | n/a | -US$1b |
| Sep 30 2021 | n/a | n/a | -US$1b |
| Jun 30 2021 | n/a | n/a | -US$888m |
| Mar 31 2021 | US$8m | US$350k | -US$809m |
Compensation vs Market: Matt's total compensation ($USD163.29M) is above average for companies of similar size in the US market ($USD13.36M).
Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.
CEO
Matt Gline (41 yo)
Mr. Matthew Gline, also known as Matt, is Independent Director of Arbutus Biopharma Corporation from February 25, 2025. Mr. Gline, also known as Matt, is Chief Executive Officer of Roivant Sciences Ltd. si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.9yrs | US$163.29m | 0.012% $ 1.9m | |
| President & CEO of Immunovant | 4.9yrs | US$11.81m | 0.17% $ 26.4m | |
| President | 4.9yrs | US$251.86m | 0% $ 0 | |
| Chief Financial Officer | 4.3yrs | US$4.13m | 0.029% $ 4.5m | |
| Chief Accounting Officer | less than a year | US$2.38m | no data | |
| President & Vant Chair | less than a year | no data | no data | |
| Chief Technology Officer | no data | no data | no data | |
| Chief Information Officer | less than a year | no data | no data | |
| General Counsel | no data | no data | no data | |
| Head of People | 3.9yrs | no data | no data | |
| Executive Vice President of Roivant Health | no data | no data | no data | |
| Chief Operating Officer of Roivant Platforms | no data | no data | no data |
Experienced Management: ROIV's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.3yrs | US$163.29m | 0.012% $ 1.9m | |
| President | 2.1yrs | US$251.86m | 0% $ 0 | |
| Independent Director | 2.8yrs | US$482.91k | 0.0041% $ 640.0k | |
| Independent Director | 11.9yrs | US$476.66k | 0.28% $ 43.5m | |
| Independent Director | 4.3yrs | US$473.84k | 0.014% $ 2.1m | |
| Independent Director | 5.9yrs | US$484.41k | 1.29% $ 201.4m | |
| Independent Director | 3.5yrs | US$489.41k | 0.0061% $ 953.0k | |
| Independent Chairman | 11.9yrs | US$521.55k | 0.015% $ 2.3m |
Experienced Board: ROIV's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 09:07 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Roivant Sciences Ltd. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chi Meng Fong | BofA Global Research |
| Louise Chen | Cantor Fitzgerald & Co. |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |